A Phase 2 interventional study of MEDI3506 and Placebo in Atopic Dermatitis, sponsored by AstraZeneca. Completed at 38 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 214th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 202 in phase 2, and was the 351st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 58 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
Each participant will be assigned randomly to a treatment arm, which could be different strengths of the active treatment or a placebo which does not contain active treatment. Both Participants and investigators will be masked to the treatment assignment.
Approximately 152 participants will take part in this study. There is a 4 weeks screening period to determine eligibility. After eligibility is confirmed, participants will receive investigational drug or placebo during the 16 weeks treatment period. This is then followed by an 8-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets at minimum 1 of the criteria, as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive multiple doses of MEDI3506 at dose level 1.
Drug: MEDI3506
Participant will receive multiple doses of MEDI3506 at dose level 2.
Drug: MEDI3506
Participant will receive multiple doses of MEDI3506 at dose level 3.
Drug: MEDI3506
Participant will receive multiple doses of Placebo
Drug: Placebo
multiple doses
multiple doses
Percent Change From Baseline to Week 16 in EASI Score
The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.
Time frame: Week 16
Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.
Time frame: Week 16
Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.
Time frame: Week 16
Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.
Time frame: Week 16
Percentage of Subjects Achieving an IGA of 0 (Clear) or 1 (Almost Clear) With at Least a 2 Grade Reduction From Baseline Score at Week 16
The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).
Time frame: Week 16
Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
Time frame: Week 16
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
Time frame: Week 16
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS
Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.
Time frame: Week 16
SCORAD: Percent Change From Baseline to Week 16
SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.
Time frame: Week 16
Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD
Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.
Time frame: Week 16
Change From Baseline to Week 16 in DLQI
The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all ⁄not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.
Time frame: Week 16
Patient Description of Atopic Dermatitis or Eczema From Patient Global Impression of Severity at Week 16
The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".
Time frame: Week 16
Change From Baseline to Week 16 in POEM
The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease
Time frame: Week 16
Change From Baseline to Week 16 in 5-D Itch
The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome
Time frame: Week 16
Occurrence of Adverse Events
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: up to 24 weeks
Oral or Tympanic Temperature Taken During Vital Signs Assessment
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
Systolic Blood Pressure Taken During Vital Signs Assessment
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
Heart Rate Taken During Vital Signs Assessment
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
Respiratory Rate Collected During Vital Signs Assessment
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: up to 24 weeks
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: up to 24 weeks
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: up to 24 weeks
Heart Rate (Beats/Min) Recorded on ECGs
Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
QT (Miliseconds) Recorded on ECGs
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline, week 16 and week 24
Number of Participants With Investigator's Overall ECGs Evaluations, e.g. Normal/Abnormal and Their Clinical Significance
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Week 16 and week 24
Left Ventricular Ejection Fraction Measured by Echocardiogram
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Time frame: Baseline and week 16
Serum MEDI3506 Concentration Profiles
To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.
Time frame: Week 16 and week 24
Occurence of Anti-drug Antibody During the Treatment and Follow-up Periods
To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.
Time frame: up to 24 weeks
| Milestone | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Started | 56 | 19 | 18 | 55 |
| Completed | 42 | 16 | 13 | 42 |
| Not completed | 14 | 3 | 5 | 13 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 10 | 2 | 5 | 7 |
| Withdrew: Other reason, unspecified | 3 | 1 | 0 | 2 |
The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.
| Percentage of change from baseline | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Percent change from baseline to Week 16 in EASI score analysed using MCP-mod dose response model | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Percent change from baseline to Week 16 in EASI score analysed using a repeated measures mixed model | -51.31 ± 5.214 | -50.03 ± 7.419 | -45.43 ± 8.402 | -53.02 ± 4.858 |
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16 | 0 | 0 | 1 | 3 |
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16 | 4 | 2 | 1 | 10 |
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16 | 12 | 5 | 5 | 16 |
The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| IGA response rate at Week 16 | 1 | 1 | 0 | 5 |
| IGA response rate at Week 16 using MCP-Mod dose-response analysis | NA | NA | NA | NA |
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS | 9 | 3 | 3 | 12 |
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
| Scores on a scale | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS | -1.41 ± 0.356 | -1.06 ± 0.519 | -2.01 ± 0.595 | -2.24 ± 0.348 |
Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.
| Scores on a scale | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS | -1.44 ± 2.39 | -1.66 ± 2.62 | -1.52 ± 1.61 | -1.63 ± 2.30 |
SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.
| Percentage of change from baseline | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| SCORAD: Percent Change From Baseline to Week 16 | -31.79 ± 25.09 | -29.88 ± 23.14 | -36.22 ± 25.34 | -39.42 ± 25.44 |
Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.
| Percentage of body surface area | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD | -17.81 ± 17.09 | -11.07 ± 10.92 | -9.46 ± 13.23 | -23.13 ± 19.35 |
The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all ⁄not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.
| Scores on scale | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in DLQI | -2.9 ± 5.3 | -2.1 ± 6.5 | -2.4 ± 4.9 | -2.7 ± 4.9 |
The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| No symptoms | 1 | 0 | 1 | 1 |
| Very mild | 5 | 0 | 5 | 10 |
| Mild | 9 | 4 | 2 | 8 |
| Moderate | 11 | 5 | 1 | 14 |
| Severe | 11 | 4 | 2 | 6 |
| Very severe | 1 | 2 | 1 | 1 |
| Missing data | 18 | 4 | 6 | 15 |
The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease
| Scores on scale | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in POEM | -5.4 ± 7.9 | -2.5 ± 4.8 | -3.7 ± 8.7 | -6.3 ± 6.9 |
The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome
| Scores on scale | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Change From Baseline to Week 16 in 5-D Itch | -3.0 ± 4.9 | -3.0 ± 2.6 | -3.8 ± 3.4 | -4.0 ± 5.1 |
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| At least one adverse event | 37 | 9 | 14 | 32 |
| At least one investigational product related event | 7 | 3 | 7 | 8 |
| At least one event of ≥ grade 3 severity | 7 | 2 | 2 | 5 |
| At least one serious event | 2 | 0 | 2 | 1 |
| At least one investigational product related serious event | 0 | 0 | 1 | 0 |
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| degrees C | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 36.46 ± 0.35 | 36.43 ± 0.52 | 36.41 ± 0.43 | 36.52 ± 0.39 |
| Week 16 | 36.49 ± 0.36 | 36.71 ± 0.41 | 36.50 ± 0.32 | 36.47 ± 0.39 |
| Week 24 | 36.44 ± 0.43 | 36.63 ± 0.50 | 36.55 ± 0.42 | 36.51 ± 0.37 |
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| mmHg | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 117.7 ± 12.9 | 119.3 ± 9.2 | 123.8 ± 9.9 | 121.5 ± 12.5 |
| Week 16 | 117.8 ± 9.6 | 117.3 ± 7.2 | 120.7 ± 13.6 | 119.8 ± 10.6 |
| Week 24 | 118.9 ± 11.1 | 117.6 ± 11.4 | 120.1 ± 15.1 | 120.6 ± 12.1 |
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Pulse Rate (beats/min) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 68.1 ± 9.8 | 66.6 ± 8.7 | 71.3 ± 9.3 | 68.2 ± 11.1 |
| Week 16 | 69.4 ± 10.1 | 66.9 ± 10.6 | 65.9 ± 8.6 | 66.4 ± 11.0 |
| Week 24 | 72.0 ± 13.5 | 67.0 ± 10.4 | 74.1 ± 8.7 | 67.6 ± 10.1 |
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| breaths/min | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 15.4 ± 2.2 | 16.0 ± 1.5 | 16.2 ± 1.8 | 15.5 ± 1.8 |
| Week 16 | 16.0 ± 2.3 | 15.7 ± 1.8 | 16.3 ± 1.9 | 15.9 ± 1.4 |
| Week 24 | 15.8 ± 2.4 | 16.1 ± 1.5 | 17.1 ± 2.4 | 15.6 ± 1.6 |
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Basophils — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Basophils — At Least One Post-Baseline Value Above ULN | 3 | 0 | 0 | 0 |
| Basophils — Values within normal range | 53 | 19 | 18 | 55 |
| Eosinophils — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Eosinophils — At Least One Post-Baseline Value Above ULN | 22 | 4 | 5 | 14 |
| Eosinophils — Values within normal range | 34 | 15 | 13 | 41 |
| Hematocrit — At Least One Post-Baseline Value Below LLN | 4 | 3 | 2 | 7 |
| Hematocrit — At Least One Post-Baseline Value Above ULN | 0 | 0 | 1 | 0 |
| Hematocrit — Values within normal range | 52 | 16 | 15 | 48 |
| Haemoglobin — At Least One Post-Baseline Value Below LLN | 5 | 1 | 3 | 8 |
| Haemoglobin — At Least One Post-Baseline Value Above ULN | 0 | 0 | 1 | 0 |
| Haemoglobin — Values within normal range | 51 | 18 | 14 | 47 |
| Lymphocytes — At Least One Post-Baseline Value Below LLN | 6 | 0 | 3 | 10 |
| Lymphocytes — At Least One Post-Baseline Value Above ULN | 0 | 0 | 0 | 0 |
| Lymphocytes — Values within normal range | 50 | 19 | 15 | 45 |
| Monocytes — At Least One Post-Baseline Value Below LLN | 1 | 0 | 1 | 3 |
| Monocytes — At Least One Post-Baseline Value Above ULN | 2 | 0 | 2 | 3 |
| Monocytes — Values within normal range | 53 | 19 | 15 | 49 |
| Platelet count — At Least One Post-Baseline Value Below LLN | 1 | 1 | 0 | 0 |
| Platelet count — At Least One Post-Baseline Value Above ULN | 3 | 0 | 2 | 5 |
| Platelet count — Values within normal range | 52 | 18 | 16 | 50 |
| Erythrocytes — At Least One Post-Baseline Value Below LLN | 10 | 3 | 4 | 17 |
| Erythrocytes — At Least One Post-Baseline Value Above ULN | 0 | 0 | 0 | 0 |
| Erythrocytes — Values within normal range | 46 | 16 | 14 | 38 |
| White blood cell count — At Least One Post-Baseline Value Below LLN | 7 | 1 | 2 | 6 |
| White blood cell count — At Least One Post-Baseline Value Above ULN | 5 | 2 | 0 | 2 |
| White blood cell count — Values within normal range | 44 | 16 | 16 | 47 |
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Albumin — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Albumin — At Least One Post-Baseline Value Above ULN | 21 | 5 | 6 | 15 |
| Albumin — Values within normal range | 35 | 14 | 12 | 40 |
| Alkaline Phosphatase — At Least One Post-Baseline Value Below LLN | 3 | 0 | 0 | 2 |
| Alkaline Phosphatase — At Least One Post-Baseline Value Above ULN | 3 | 2 | 2 | 4 |
| Alkaline Phosphatase — Values within normal range | 50 | 17 | 16 | 49 |
| Alanine Aminotransferase — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase — At Least One Post-Baseline Value Above ULN | 7 | 4 | 4 | 5 |
| Alanine Aminotransferase — Values within normal range | 49 | 15 | 14 | 50 |
| Aspartate Aminotransferase — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase — At Least One Post-Baseline Value Above ULN | 6 | 3 | 3 | 8 |
| Aspartate Aminotransferase — Values within normal range | 50 | 16 | 15 | 47 |
| Bilirubin — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Bilirubin — At Least One Post-Baseline Value Above ULN | 3 | 0 | 1 | 1 |
| Bilirubin — Values within normal range | 53 | 19 | 17 | 54 |
| Urea Nitrogen — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Urea Nitrogen — At Least One Post-Baseline Value Above ULN | 0 | 0 | 0 | 2 |
| Urea Nitrogen — Values within normal range | 56 | 19 | 18 | 53 |
| Creatinine — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Creatinine — At Least One Post-Baseline Value Above ULN | 0 | 0 | 1 | 3 |
| Creatinine — Values within normal range | 56 | 19 | 17 | 52 |
| Gamma Glutamyl Transferase — At Least One Post-Baseline Value Below LLN | 4 | 2 | 0 | 5 |
| Gamma Glutamyl Transferase — At Least One Post-Baseline Value Above ULN | 2 | 3 | 2 | 1 |
| Gamma Glutamyl Transferase — Values within normal range | 50 | 14 | 16 | 49 |
| Potassium — At Least One Post-Baseline Value Below LLN | 1 | 1 | 0 | 1 |
| Potassium — At Least One Post-Baseline Value Above ULN | 1 | 0 | 1 | 1 |
| Potassium — Values within normal range | 54 | 18 | 17 | 53 |
| Sodium — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Sodium — At Least One Post-Baseline Value Above ULN | 2 | 0 | 0 | 2 |
| Sodium — Values within normal range | 54 | 19 | 18 | 53 |
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| pH — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| pH — At Least One Post-Baseline Value Above ULN | 0 | 0 | 0 | 1 |
| pH — Values within normal range | 56 | 19 | 18 | 54 |
| Erythrocytes — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Erythrocytes — At Least One Post-Baseline Value Above ULN | 8 | 2 | 1 | 6 |
| Erythrocytes — Values within normal range | 48 | 17 | 17 | 49 |
| Specific gravity — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Specific gravity — At Least One Post-Baseline Value Above ULN | 4 | 0 | 3 | 7 |
| Specific gravity — Values within normal range | 52 | 19 | 15 | 48 |
| Leukocytes — At Least One Post-Baseline Value Below LLN | 0 | 0 | 0 | 0 |
| Leukocytes — At Least One Post-Baseline Value Above ULN | 4 | 2 | 1 | 5 |
| Leukocytes — Values within normal range | 52 | 17 | 17 | 50 |
Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| beats per minute | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 67.59 ± 9.82 | 65.61 ± 6.87 | 72.63 ± 9.82 | 65.18 ± 9.43 |
| Week 16 | 66.02 ± 9.97 | 63.80 ± 8.56 | 65.42 ± 9.08 | 63.05 ± 10.61 |
| Week 24 | 68.17 ± 13.94 | 63.88 ± 10.41 | 72.46 ± 9.12 | 64.58 ± 9.43 |
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| milliseconds | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 385.43 ± 27.75 | 390.67 ± 20.57 | 380.04 ± 26.38 | 390.27 ± 22.69 |
| Week 16 | 387.05 ± 26.14 | 390.40 ± 24.24 | 395.75 ± 20.36 | 391.95 ± 29.22 |
| Week 24 | 385.88 ± 34.31 | 398.69 ± 28.52 | 383.15 ± 19.05 | 393.40 ± 26.54 |
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Week 16 — Abnormal ECG: Clinically significant | 0 | 0 | 0 | 0 |
| Week 16 — Abnormal ECG: Not Clinically significant | 3 | 2 | 2 | 10 |
| Week 16 — Normal ECG | 38 | 13 | 10 | 32 |
| Week 16 — Missing | 15 | 4 | 6 | 13 |
| Week 24 — Abnormal ECG: Clinically significant | 0 | 0 | 0 | 0 |
| Week 24 — Abnormal ECG: Not Clinically significant | 4 | 4 | 2 | 11 |
| Week 24 — Normal ECG | 38 | 12 | 11 | 29 |
| Week 24 — Missing | 14 | 3 | 5 | 15 |
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
| % LVEF | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline | 64.3 ± 6.3 | 64.7 ± 6.2 | 62.8 ± 5.2 | 63.6 ± 4.7 |
| Week 16 | 64.3 ± 5.9 | 63.0 ± 4.4 | 61.0 ± 3.6 | 65.2 ± 5.1 |
To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.
| μg/mL | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|
| Week 16 | 0.377 ± 242 | 2.158 ± 193 | 5.979 ± 118 |
| Week 24 | 0.018 ± 184 | 0.118 ± 298 | 0.188 ± 234 |
To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.
| Participants | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Baseline ADA result | 1 | 0 | 0 | 0 |
| Post-baseline ADA result | 1 | 1 | 0 | 2 |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/56 (0%) | 2/56 (3.6%) | 29/56 (51.8%) |
| MEDI3506 Dose 1 | 0/19 (0%) | 0/19 (0%) | 11/19 (57.9%) |
| MEDI3506 Dose 2 | 0/18 (0%) | 2/18 (11.1%) | 14/18 (77.8%) |
| MEDI3506 Dose 3 | 0/55 (0%) | 1/55 (1.8%) | 25/55 (45.5%) |
| Event | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Covid-19 pneumoniaInfections and infestations | 0/56 | 0/19 | 1/18 | 0/55 |
| Venous thrombosis limbVascular disorders | 0/56 | 0/19 | 1/18 | 0/55 |
| Medical device removalSurgical and medical procedures | 0/56 | 0/19 | 0/18 | 1/55 |
| Food allergyImmune system disorders | 1/56 | 0/19 | 0/18 | 0/55 |
| Dermatitis exfoliative generalisedSkin and subcutaneous tissue disorders | 1/56 | 0/19 | 0/18 | 0/55 |
| Event | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 12/56 | 2/19 | 0/18 | 14/55 |
| Covid-19Infections and infestations | 7/56 | 0/19 | 0/18 | 2/55 |
| NasopharyngitisInfections and infestations | 1/56 | 1/19 | 2/18 | 3/55 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/56 | 0/19 | 2/18 | 0/55 |
| EczemaSkin and subcutaneous tissue disorders | 3/56 | 0/19 | 2/18 | 2/55 |
| PruritusSkin and subcutaneous tissue disorders | 3/56 | 1/19 | 2/18 | 1/55 |
| Injection site reactionGeneral disorders | 0/56 | 0/19 | 1/18 | 4/55 |
| Injection site bruisingGeneral disorders | 0/56 | 0/19 | 1/18 | 1/55 |
| Injection site swellingGeneral disorders | 1/56 | 0/19 | 1/18 | 0/55 |
| BronchitisInfections and infestations | 0/56 | 0/19 | 1/18 | 0/55 |
| Age, Continuous(Years) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | Total |
|---|---|---|---|---|---|
| Mean | 32.3 ± 11.4 | 28.7 ± 8.9 | 37.9 ± 14.3 | 34.6 ± 11.8 | 33.4 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | Total |
|---|---|---|---|---|---|
| Female | 27 | 8 | 7 | 25 | 67 |
| Male | 29 | 11 | 11 | 30 | 81 |
| Race/Ethnicity, Customized(Participants) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | Total |
|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 | 0 | 0 |
| ASIAN | 8 | 5 | 3 | 6 | 22 |
| BLACK OR AFRICAN AMERICAN | 1 | 1 | 2 | 2 | 6 |
| MULTIPLE CATEGORIES CHECKED | 1 | 0 | 1 | 0 | 2 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 | 0 | 0 |
| OTHER | 0 | 0 | 1 | 2 | 3 |
| WHITE | 46 | 13 | 11 | 45 | 115 |
| Region of Enrollment(Participants) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | Total |
|---|---|---|---|---|---|
| USA | 6 | 0 | 3 | 7 | 16 |
| Australia | 0 | 0 | 1 | 1 | 2 |
| Germany | 5 | 1 | 3 | 2 | 11 |
| Spain | 7 | 0 | 0 | 5 | 12 |
| United Kingdom | 34 | 13 | 9 | 35 | 91 |
| Poland | 4 | 5 | 2 | 5 | 16 |
| Eczema Area and Severity Index (EASI) score(Scores on a scale) | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | Total |
|---|---|---|---|---|---|
| Mean | 28.81 ± 8.90 | 28.94 ± 11.66 | 28.36 ± 11.87 | 32.30 ± 10.86 | 30.07 ± 10.43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2019 to primary completion in Jul 2022, 31 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 31 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tozorakimab